Adeno-Associated Virus Gene Therapy: Translational Progress and Future Prospects in the Treatment of Heart Failure

Heart Lung and Circulation

Volumn 27, Issue 11, 2018, Pages 1285-1300

  Bass Stringer, Sebastian ^a,b   Bernardo, Bianca C ^a,c,d   May, Clive N ^c   Thomas, Colleen J ^b,c   Weeks, Kate L ^a,d   McMullen, Julie R ^a,b,d  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Adeno associated virus; Gene therapy; Heart failure; Large animal models

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; ADENO ASSOCIATED VIRUS VECTOR; BETA ADRENERGIC RECEPTOR; CALCIUM BINDING PROTEIN; HEME OXYGENASE 1; NEUTRALIZING ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; S100A1 PROTEIN; SERCA2A PROTEIN; SUMO 1 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADRENERGIC SYSTEM; ANGIOGENESIS; BETA ADRENERGIC SENSITIVITY; CHIMERA; CYTOMEGALOVIRUS; DISEASE MODEL; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENETIC TRANSDUCTION; HEART FAILURE; HEART MUSCLE CONTRACTILITY; INFLAMMATION; METABOLISM; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SIGNAL TRANSDUCTION; TRANSGENE; VIRAL GENE THERAPY; ANIMAL; ANIMAL MODEL; DEPENDOPARVOVIRUS; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; PROCEDURES;

ANIMALS; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HEART FAILURE; HUMANS; MODELS, ANIMAL;

EID: 85046129894     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2018.03.005     Document Type: Review

References (124)

1. Savarese, G., Lund, L.H., Global public health burden of heart failure. Card Fail Rev 3 (2017), 7–11.
2. Taylor, C.J., Ryan, R., Nichols, L., Gale, N., Hobbs, F.R., Marshall, T., Survival following a diagnosis of heart failure in primary care. Fam Pract 34 (2017), 161–168.
3. Daya, S., Berns, K.I., Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21 (2008), 583–593.
4. Wold, W.S., Toth, K., Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther 13 (2013), 421–433.
5. Connolly, J.B., Lentiviruses in gene therapy clinical research. Gene Ther 9 (2002), 1730–1734.
6. Ramamoorth, M., Narvekar, A., Non viral vectors in gene therapy—an overview. J Clin Diagn Res 9 (2015), GE01–6.
7. Savic, N., Schwank, G., Advances in therapeutic CRISPR/Cas9 genome editing. Transl Res 168 (2016), 15–21.
8. Zinn, E., Vandenberghe, L.H., Adeno-associated virus: fit to serve. Curr Opin Virol 8 (2014), 90–97.
9. Ghosh, A., Duan, D., Expanding adeno-associated viral vector capacity: a tale of two vectors. Biotechnol Genet Eng Rev 24 (2007), 165–177.
10. Deyle, D.R., Russell, D.W., Adeno-associated virus vector integration. Curr Opin Mol Ther 11 (2009), 442–447.
11. Zaiss, A.K., Liu, Q., Bowen, G.P., Wong, N.C., Bartlett, J.S., Muruve, D.A., Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 76 (2002), 4580–4590.
12. Vandendriessche, T., Thorrez, L., Acosta-Sanchez, A., Petrus, I., Wang, L., Ma, L., et al. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost 5 (2007), 16–24.
13. Athanasopoulos, T., Fabb, S., Dickson, G., Gene therapy vectors based on adeno-associated virus: characteristics and applications to acquired and inherited diseases (review). Int J Mol Med 6 (2000), 363–375.
14. Sun, J.Y., Anand-Jawa, V., Chatterjee, S., Wong, K.K., Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther 10 (2003), 964–976.
15. Hammoudi, N., Ishikawa, K., Hajjar, R.J., Adeno-associated virus-mediated gene therapy in cardiovascular disease. Curr Opin Cardiol 30 (2015), 228–234.
16. Vassalli, G., Bueler, H., Dudler, J., von Segesser, L.K., Kappenberger, L., Adeno-associated virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in vivo: a comparative study with adenovirus vectors. Int J Cardiol 90 (2003), 229–238.
17. St George, J.A., Gene therapy progress and prospects: adenoviral vectors. Gene Ther 10 (2003), 1135–1141.
18. Farraha, M., Chong, J.J., Kizana, E., Therapeutic prospects of gene therapy for atrial fibrillation. Heart Lung Circ 25 (2016), 808–813.
19. Hauck, B., Xiao, W., Characterization of tissue tropism determinants of adeno-associated virus type 1. J Virol 77 (2003), 2768–2774.
20. Zincarelli, C., Soltys, S., Rengo, G., Koch, W.J., Rabinowitz, J.E., Comparative cardiac gene delivery of adeno-associated virus serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart. Clin Transl Sci 3 (2010), 81–89.
21. Palomeque, J., Chemaly, E.R., Colosi, P., Wellman, J.A., Zhou, S., Del Monte, F., et al. Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo. Gene Ther 14 (2007), 989–997.
22. Wang, Z., Zhu, T., Qiao, C., Zhou, L., Wang, B., Zhang, J., et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 23 (2005), 321–328.
23. Gao, G., Bish, L.T., Sleeper, M.M., Mu, X., Sun, L., Lou, Y., et al. Transendocardial delivery of AAV6 results in highly efficient and global cardiac gene transfer in rhesus macaques. Hum Gene Ther 22 (2011), 979–984.
24. Bish, L.T., Morine, K., Sleeper, M.M., Sanmiguel, J., Wu, D., Gao, G., et al. Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther 19 (2008), 1359–1368.
25. Muller, O.J., Leuchs, B., Pleger, S.T., Grimm, D., Franz, W.M., Katus, H.A., et al. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res 70 (2006), 70–78.
26. Pacak, C.A., Mah, C.S., Thattaliyath, B.D., Conlon, T.J., Lewis, M.A., Cloutier, D.E., et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 99 (2006), e3–e9.
27. Asokan, A., Conway, J.C., Phillips, J.L., Li, C., Hegge, J., Sinnott, R., et al. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol 28 (2010), 79–82.
28. Pulicherla, N., Shen, S., Yadav, S., Debbink, K., Govindasamy, L., Agbandje-McKenna, M., et al. Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol Ther 19 (2011), 1070–1078.
29. Yang, L., Jiang, J., Drouin, L.M., Agbandje-McKenna, M., Chen, C., Qiao, C., et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci U S A 106 (2009), 3946–3951.
30. Damdindorj, L., Karnan, S., Ota, A., Hossain, E., Konishi, Y., Hosokawa, Y., et al. A comparative analysis of constitutive promoters located in adeno-associated viral vectors. PLoS One, 9, 2014, e106472.
31. Gregorevic, P., Blankinship, M.J., Allen, J.M., Crawford, R.W., Meuse, L., Miller, D.G., et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 10 (2004), 828–834.
32. Weeks, K.L., Gao, X., Du, X.J., Boey, E.J., Matsumoto, A., Bernardo, B.C., et al. Phosphoinositide 3-kinase p110alpha is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction. Circ Heart Fail 5 (2012), 523–534.
33. Pacak, C.A., Sakai, Y., Thattaliyath, B.D., Mah, C.S., Byrne, B.J., Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice. Genet Vaccines Ther, 6, 2008, 13.
34. Pleger, S.T., Shan, C., Ksienzyk, J., Bekeredjian, R., Boekstegers, P., Hinkel, R., et al. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med, 3, 2011, 92ra64.
35. Raake, P.W., Schlegel, P., Ksienzyk, J., Reinkober, J., Barthelmes, J., Schinkel, S., et al. AAV6.betaARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J 34 (2013), 1437–1447.
36. Kolwicz, S.C. Jr., Odom, G.L., Nowakowski, S.G., Moussavi-Harami, F., Chen, X., Reinecke, H., et al. AAV6-mediated cardiac-specific overexpression of ribonucleotide reductase enhances myocardial contractility. Mol Ther 24 (2016), 240–250.
37. Teichman, S.L., Thomson, K.S., Regnier, M., Cardiac myosin activation with gene therapy produces sustained inotropic effects and may treat heart failure with reduced ejection fraction. Handb Exp Pharmacol 243 (2017), 447–464.
38. Mearini, G., Stimpel, D., Geertz, B., Weinberger, F., Kramer, E., Schlossarek, S., et al. Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice. Nat Commun, 5, 2014, 5515.
39. Woitek, F., Zentilin, L., Hoffman, N.E., Powers, J.C., Ottiger, I., Parikh, S., et al. Intracoronary cytoprotective gene therapy: a study of VEGF-B167 in a pre-clinical animal model of dilated cardiomyopathy. J Am Coll Cardiol 66 (2015), 139–153.
40. Nishikimi, T., Kuwahara, K., Nakao, K., Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol 57 (2011), 131–140.
41. Calcedo, R., Wilson, J.M., Humoral immune response to AAV. Front Immunol, 4, 2013, 341.
42. Madsen, D., Cantwell, E.R., O'Brien, T., Johnson, P.A., Mahon, B.P., Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1. J Gen Virol 90 (2009), 2622–2633.
43. Mingozzi, F., High, K.A., Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122 (2013), 23–36.
44. Masat, E., Pavani, G., Mingozzi, F., Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions. Discov Med 15 (2013), 379–389.
45. Blacklow, N.R., Hoggan, M.D., Rowe, W.P., Serologic evidence for human infection with adenovirus-associated viruses. J Natl Cancer Inst 40 (1968), 319–327.
46. Parks, W.P., Boucher, D.W., Melnick, J.L., Taber, L.H., Yow, M.D., Seroepidemiological and ecological studies of the adenovirus-associated satellite viruses. Infect Immun 2 (1970), 716–722.
47. Sprecher-Goldberger, S., Thiry, L., Lefebvre, N., Dekegel, D., de Halleux, F., Complement-fixation antibodies to adenovirus-associated viruses, cytomegaloviruses and herpes simplex viruses in patients with tumors and in control individuals. Am J Epidemiol 94 (1971), 351–358.
48. Arruda, V.R., Xiao, W., It's all about the clothing: capsid domination in the adeno-associated viral vector world. J Thromb Haemost 5 (2007), 12–15.
49. Liang, Y., Mathiyalagan, P., Kohlbrenner, E., Chepurko, E., Jeong, D., Ceholski, D., et al. Abstract 15439: AAV-containing exosomes as a novel vector to improve AAV-mediated myocardial gene delivery in resistance to neutralizing antibody. Circulation, 136, 2017.
50. Hulot, J.S., Ishikawa, K., Hajjar, R.J., Gene therapy for the treatment of heart failure: promise postponed. Eur Heart J 37 (2016), 1651–1658.
51. Chamberlain, K., Riyad, J.M., Weber, T., Cardiac gene therapy with adeno-associated virus-based vectors. Curr Opin Cardiol 27 (2017), 5–82.
52. Ishikawa, K., Tilemann, L., Ladage, D., Aguero, J., Leonardson, L., Fish, K., et al. Cardiac gene therapy in large animals: bridge from bench to bedside. Gene Ther 19 (2012), 670–677.
53. Hajjar, R.J., Potential of gene therapy as a treatment for heart failure. J Clin Invest 123 (2013), 53–61.
54. Scimia, M.C., Cannavo, A., Koch, W.J., Gene therapy for heart disease: molecular targets, vectors and modes of delivery to myocardium. Expert Rev Cardiovasc Ther 11 (2013), 999–1013.
55. Kotin, R.M., Large-scale recombinant adeno-associated virus production. Hum Mol Genet 20 (2011), R2–R6.
56. Feng, L., Guo, M., Zhang, S., Chu, J., Zhuang, Y., Zhang, S., Optimization of transfection mediated by calcium phosphate for plasmid rAAV-LacZ (recombinant adeno-associated virus-beta-galactosidase reporter gene) production in suspension-cultured HEK-293 (human embryonic kidney 293) cells. Biotechnol Appl Biochem 46 (2007), 127–135.
57. Urabe, M., Ding, C., Kotin, R.M., Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 13 (2002), 1935–1943.
58. Bera, A., Sen, D., Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases. Heart Fail Rev 22 (2017), 795–823.
59. Rockman, H.A., Koch, W.J., Lefkowitz, R.J., Seven-transmembrane-spanning receptors and heart function. Nature 415 (2002), 206–212.
60. Reinkober, J., Tscheschner, H., Pleger, S.T., Most, P., Katus, H.A., Koch, W.J., et al. Targeting GRK2 by gene therapy for heart failure: benefits above beta-blockade. Gene Ther 19 (2012), 686–693.
61. Shiojima, I., Sato, K., Izumiya, Y., Schiekofer, S., Ito, M., Liao, R., et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115 (2005), 2108–2118.
62. Ferrarini, M., Arsic, N., Recchia, F.A., Zentilin, L., Zacchigna, S., Xu, X., et al. Adeno-associated virus-mediated transduction of VEGF165 improves cardiac tissue viability and functional recovery after permanent coronary occlusion in conscious dogs. Circ Res 98 (2006), 954–961.
63. Tao, Z., Chen, B., Tan, X., Zhao, Y., Wang, L., Zhu, T., et al. Coexpression of VEGF and angiopoietin-1 promotes angiogenesis and cardiomyocyte proliferation reduces apoptosis in porcine myocardial infarction (MI) heart. Proc Natl Acad Sci U S A 108 (2011), 2064–2069.
64. Hasenfuss, G., Reinecke, H., Studer, R., Meyer, M., Pieske, B., Holtz, J., et al. Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium. Circ Res 75 (1994), 434–442.
65. Rincon, M.Y., VandenDriessche, T., Chuah, M.K., Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation. Cardiovasc Res 108 (2015), 4–20.
66. Beeri, R., Chaput, M., Guerrero, J.L., Kawase, Y., Yosefy, C., Abedat, S., et al. Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation. Circ Heart Fail 3 (2010), 627–634.
67. Jaski, B.E., Jessup, M.L., Mancini, D.M., Cappola, T.P., Pauly, D.F., Greenberg, B., et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 15 (2009), 171–181.
68. Jessup, M., Greenberg, B., Mancini, D., Cappola, T., Pauly, D.F., Jaski, B., et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 124 (2011), 304–313.
69. Greenberg, B., Butler, J., Felker, G.M., Ponikowski, P., Voors, A.A., Desai, A.S., et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet 387 (2016), 1178–1186.
70. Kho, C., Lee, A., Jeong, D., Oh, J.G., Chaanine, A.H., Kizana, E., et al. SUMO1-dependent modulation of SERCA2a in heart failure. Nature 477 (2011), 601–605.
71. Tilemann, L., Lee, A., Ishikawa, K., Aguero, J., Rapti, K., Santos-Gallego, C., et al. SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure. Sci Transl Med, 5, 2013, 211ra159.
72. Duarte-Costa, S., Castro-Ferreira, R., Neves, J.S., Leite-Moreira, A.F., S100A1: a major player in cardiovascular performance. Physiol Res 63 (2014), 669–681.
73. Yamasaki, R., Berri, M., Wu, Y., Trombitas, K., McNabb, M., Kellermayer, M.S., et al. Titin-actin interaction in mouse myocardium: passive tension modulation and its regulation by calcium/S100A1. Biophys J 81 (2001), 2297–2313.
74. Most, P., Boerries, M., Eicher, C., Schweda, C., Volkers, M., Wedel, T., et al. Distinct subcellular location of the Ca2+-binding protein S100A1 differentially modulates Ca2+-cycling in ventricular rat cardiomyocytes. J Cell Sci 118 (2005), 421–431.
75. Ehlermann, P., Remppis, A., Guddat, O., Weimann, J., Schnabel, P.A., Motsch, J., et al. Right ventricular upregulation of the Ca(2+) binding protein S100A1 in chronic pulmonary hypertension. Biochim Biophys Acta 1500 (2000), 249–255.
76. Weber, C., Neacsu, I., Krautz, B., Schlegel, P., Sauer, S., Raake, P., et al. Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model. Gene Ther 21 (2014), 131–138.
77. Carr, A.N., Schmidt, A.G., Suzuki, Y., del Monte, F., Sato, Y., Lanner, C., et al. Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol 22 (2002), 4124–4135.
78. Pathak, A., del Monte, F., Zhao, W., Schultz, J.E., Lorenz, J.N., Bodi, I., et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res 96 (2005), 756–766.
79. Chen, G., Zhou, X., Nicolaou, P., Rodriguez, P., Song, G., Mitton, B., et al. A human polymorphism of protein phosphatase-1 inhibitor-1 is associated with attenuated contractile response of cardiomyocytes to beta-adrenergic stimulation. FASEB J 22 (2008), 1790–1796.
80. Fish, K.M., Ladage, D., Kawase, Y., Karakikes, I., Jeong, D., Ly, H., et al. AAV9: I-1c delivered via direct coronary infusion in a porcine model of heart failure improves contractility and mitigates adverse remodeling. Circ Heart Fail 6 (2013), 310–317.
81. Ishikawa, K., Fish, K.M., Tilemann, L., Rapti, K., Aguero, J., Santos-Gallego, C.G., et al. Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure. Mol Ther 22 (2014), 2038–2045.
82. Sawicki, K.T., Shang, M., Wu, R., Chang, H.C., Khechaduri, A., Sato, T., et al. Increased heme levels in the heart lead to exacerbated ischemic injury. J Am Heart Assoc, 4, 2015, e002272.
83. Hao, K., Hanawa, H., Ding, L., Ota, Y., Yoshida, K., Toba, K., et al. Free heme is a danger signal inducing expression of proinflammatory proteins in cultured cells derived from normal rat hearts. Mol Immunol 48 (2011), 1191–1202.
84. Hinkel, R., Lange, P., Petersen, B., Gottlieb, E., Ng, J.K., Finger, S., et al. Heme oxygenase-1 gene therapy provides cardioprotection via control of post-ischemic inflammation: an experimental study in a pre-clinical pig model. J Am Coll Cardiol 66 (2015), 154–165.
85. Bernardo, B.C., Weeks, K.L., Pretorius, L., McMullen, J.R., Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther 128 (2010), 191–227.
86. Perrino, C., Naga Prasad, S.V., Mao, L., Noma, T., Yan, Z., Kim, H.S., et al. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J Clin Invest 116 (2006), 1547–1560.
87. McMullen, J.R., Shioi, T., Zhang, L., Tarnavski, O., Sherwood, M.C., Kang, P.M., et al. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci U S A 100 (2003), 12355–12360.
88. Prakoso, D., De Blasio, M.J., Qin, C., Rosli, S., Kiriazis, H., Qian, H., et al. Phosphoinositide 3-kinase (p110alpha) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction. Clin Sci (Lond) 131 (2017), 1345–1360.
89. Houten, S.M., Wanders, R.J., A general introduction to the biochemistry of mitochondrial fatty acid beta-oxidation. J Inherit Metab Dis 33 (2010), 469–477.
90. Lin, R.C., Weeks, K.L., Gao, X.M., Williams, R.B., Bernardo, B.C., Kiriazis, H., et al. PI3K(p110 alpha) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA. Arterioscler Thromb Vasc Biol 30 (2010), 724–732.
91. Bernardo, B.C., Weeks, K.L., Pongsukwechkul, T., Gao, X., Kiriazis, H., Cemerlang, N., et al. Gene delivery of medium chain acyl-coenzyme A dehydrogenase (MCAD) induces physiological cardiac hypertrophy and protects against pathological remodelling. Clin Sci (Lond) 132 (2018), 381–397.
92. Mingozzi, F., Anguela, X.M., Pavani, G., Chen, Y., Davidson, R.J., Hui, D.J., et al. Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med, 5, 2013, 194ra92.
93. Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients With Chronic Heart Failure (SERCA-LVAD), Clinical Trials U.S National Library of Medicine. 2007.
94. AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure (AGENT-HF), Clinical Trials U.S National Library of Medicine. 2013.
95. Morrison, C., Landmark gene therapy poised for US approval. Nat Rev Drug Discov 16 (2017), 739–741.
96. Kwon, I., Schaffer, D.V., Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm Res 25 (2008), 489–499.
97. Mingozzi, F., Chen, Y., Murphy, S.L., Edmonson, S.C., Tai, A., Price, S.D., et al. Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B. Mol Ther 20 (2012), 1410–1416.
98. Mingozzi, F., Chen, Y., Edmonson, S.C., Zhou, S., Thurlings, R.M., Tak, P.P., et al. Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue. Gene Ther 20 (2013), 417–424.
99. Mimuro, J., Mizukami, H., Hishikawa, S., Ikemoto, T., Ishiwata, A., Sakata, A., et al. Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors. Mol Ther 21 (2013), 318–323.
100. Monteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.F., et al. A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol Ther 19 (2011), 2084–2091.
101. Chicoine, L.G., Montgomery, C.L., Bremer, W.G., Shontz, K.M., Griffin, D.A., Heller, K.N., et al. Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery. Mol Ther 22 (2014), 338–347.
102. Huttner, N.A., Girod, A., Perabo, L., Edbauer, D., Kleinschmidt, J.A., Buning, H., et al. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. Gene Ther 10 (2003), 2139–2147.
103. Adachi, K., Enoki, T., Kawano, Y., Veraz, M., Nakai, H., Drawing a high-resolution functional map of adeno-associated virus capsid by massively parallel sequencing. Nat Commun, 5, 2014, 3075.
104. Maheshri, N., Koerber, J.T., Kaspar, B.K., Schaffer, D.V., Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 24 (2006), 198–204.
105. Kupatt, C., Hinkel, R., Pfosser, A., El-Aouni, C., Wuchrer, A., Fritz, A., et al. Cotransfection of vascular endothelial growth factor-A and platelet-derived growth factor-B via recombinant adeno-associated virus resolves chronic ischemic malperfusion role of vessel maturation. J Am Coll Cardiol 56 (2010), 414–422.
106. Hadri, L., Bobe, R., Kawase, Y., Ladage, D., Ishikawa, K., Atassi, F., et al. SERCA2a gene transfer enhances eNOS expression and activity in endothelial cells. Mol Ther 18 (2010), 1284–1292.
107. Katz, M.G., Fargnoli, A.S., Williams, R.D., Steuerwald, N.M., Isidro, A., Ivanina, A.V., et al. Safety and efficacy of high-dose adeno-associated virus 9 encoding sarcoplasmic reticulum Ca(2+) adenosine triphosphatase delivered by molecular cardiac surgery with recirculating delivery in ovine ischemic cardiomyopathy. J Thorac Cardiovasc Surg 148 (2014), 1065–1072.
108. Katz, M.G., Brandon-Warner, E., Fargnoli, A.S., Williams, R.D., Kendle, A.P., Hajjar, R.J., et al. Mitigation of myocardial fibrosis by molecular cardiac surgery-mediated gene overexpression. J Thorac Cardiovasc Surg 151 (2016), 1191–1200.
109. Fargnoli, A.S., Katz, M.G., Yarnall, C., Isidro, A., Petrov, M., Steuerwald, N., et al. Cardiac surgical delivery of the sarcoplasmic reticulum calcium ATPase rescues myocytes in ischemic heart failure. Ann Thorac Surg 96 (2013), 586–595.
110. Mariani, J.A., Smolic, A., Preovolos, A., Byrne, M.J., Power, J.M., Kaye, D.M., Augmentation of left ventricular mechanics by recirculation-mediated AAV2/1-SERCA2a gene delivery in experimental heart failure. Eur J Heart Fail 13 (2011), 247–253.
111. Byrne, M.J., Power, J.M., Preovolos, A., Mariani, J.A., Hajjar, R.J., Kaye, D.M., Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther 15 (2008), 1550–1557.
112. Kawase, Y., Ly, H.Q., Prunier, F., Lebeche, D., Shi, Y., Jin, H., et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 51 (2008), 1112–1119.
113. Milani-Nejad, N., Janssen, P.M., Small and large animal models in cardiac contraction research: advantages and disadvantages. Pharmacol Ther 141 (2014), 235–249.
114. Yuan, R., Tsaih, S.W., Petkova, S.B., Marin de Evsikova, C., Xing, S., Marion, M.A., et al. Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels. Aging Cell 8 (2009), 277–287.
115. Hill, A.J., Iaizzo, P.A., Comparative cardiac anatomy. Iaizzo, P.A., (eds.) Handbook of cardiac anatomy, physiology, and devices, 2009, Humana Press, Totowa, NJ, 87–108.
116. Camacho, P., Fan, H., Liu, Z., He, J.Q., Large mammalian animal models of heart disease. J Cardiovasc Dev Dis, 3, 2016.
117. Byrne, M.J., Raman, J.S., Alferness, C.A., Esler, M.D., Kaye, D.M., Power, J.M., An ovine model of tachycardia-induced degenerative dilated cardiomyopathy and heart failure with prolonged onset. J Card Fail 8 (2002), 108–115.
118. Starr, C., Taggart, R., Evers, C., Starr, L., Biology: the unity and diversity of life. 14th ed., 2016, Cengage Learning.
119. McCutcheon, S.N., Blair, H.T., Purchas, R.W., Body composition and organ weights in fleeceweight-selected and control Romney rams. N Z J Agric Res 36 (1993), 445–449.
120. Dutta, S., Sengupta, P., Men and mice: relating their ages. Life Sci 152 (2016), 244–248.
121. Ho, D., Zhao, X., Gao, S., Hong, C., Vatner, D.E., Vatner, S.F., Heart rate and electrocardiography monitoring in mice. Curr Protoc Mouse Biol 1 (2011), 123–139.
122. Holliday, M.A., Potter, D., Jarrah, A., Bearg, S., The relation of metabolic rate to body weight and organ size. Pediatr Res 1 (1967), 185–195.
123. Cook, S., Togni, M., Schaub, M.C., Wenaweser, P., Hess, O.M., High heart rate: a cardiovascular risk factor. Eur Heart J 27 (2006), 2387–2393.
124. Doevendans, P.A., Daemen, M.J., de Muinck, E.D., Smits, J.F., Cardiovascular phenotyping in mice. Cardiovasc Res 39 (1998), 34–49.